MX2020010078A - Composicion farmaceutica que comprenden timolol. - Google Patents

Composicion farmaceutica que comprenden timolol.

Info

Publication number
MX2020010078A
MX2020010078A MX2020010078A MX2020010078A MX2020010078A MX 2020010078 A MX2020010078 A MX 2020010078A MX 2020010078 A MX2020010078 A MX 2020010078A MX 2020010078 A MX2020010078 A MX 2020010078A MX 2020010078 A MX2020010078 A MX 2020010078A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
timolol
topical administration
present
glaucoma
Prior art date
Application number
MX2020010078A
Other languages
English (en)
Inventor
Bernhard Hauptmeier
Frank LÖSCHER
Sonja Krösser
Kirsten Eickhoff
Diana Strehl
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2020010078A publication Critical patent/MX2020010078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden timolol bloqueador selectivo del receptor beta 1(ß1) y/o una sal farmacéuticamente aceptable del mismo y un vehículo líquido que comprende un alcano semifluorado. La composición farmacéutica de la presente invención puede ser tratamiento del glaucoma, aumento de la presión intraocular, hipertensión ocular y/o un síntoma asociado con ellos.
MX2020010078A 2018-03-28 2019-03-25 Composicion farmaceutica que comprenden timolol. MX2020010078A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18164563 2018-03-28
EP18185436 2018-07-25
PCT/EP2019/057429 WO2019185543A1 (en) 2018-03-28 2019-03-25 Pharmaceutical composition comprising timolol

Publications (1)

Publication Number Publication Date
MX2020010078A true MX2020010078A (es) 2021-02-26

Family

ID=65818028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010078A MX2020010078A (es) 2018-03-28 2019-03-25 Composicion farmaceutica que comprenden timolol.

Country Status (12)

Country Link
US (1) US20210121471A1 (es)
EP (1) EP3773469A1 (es)
JP (1) JP7496778B2 (es)
KR (1) KR20200136403A (es)
CN (1) CN111867560A (es)
AU (1) AU2019246035A1 (es)
BR (1) BR112020017841A2 (es)
CA (1) CA3091313A1 (es)
IL (1) IL276888A (es)
MX (1) MX2020010078A (es)
SG (1) SG11202007860XA (es)
WO (1) WO2019185543A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
TWI298257B (en) * 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
EP1507513A1 (de) * 2002-05-24 2005-02-23 Dr. GERHARD MANN chem.-pharm. Fabrik GmbH Tropfbares ophthalmisches gelpräparat mit diclofenamid und timolol
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
WO2008157614A2 (en) * 2007-06-21 2008-12-24 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) * 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
JP2012250951A (ja) 2011-06-06 2012-12-20 Santen Pharmaceut Co Ltd アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤
JP6704400B2 (ja) * 2014-10-20 2020-06-03 センティス・ファーマ・プライヴェート・リミテッド 眼科用液剤
WO2016082644A1 (en) * 2014-11-26 2016-06-02 The University Of Hong Kong A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트

Also Published As

Publication number Publication date
CN111867560A (zh) 2020-10-30
JP2021518352A (ja) 2021-08-02
EP3773469A1 (en) 2021-02-17
BR112020017841A2 (pt) 2020-12-22
WO2019185543A1 (en) 2019-10-03
KR20200136403A (ko) 2020-12-07
SG11202007860XA (en) 2020-09-29
IL276888A (en) 2020-10-29
CA3091313A1 (en) 2019-10-03
US20210121471A1 (en) 2021-04-29
AU2019246035A1 (en) 2020-09-10
JP7496778B2 (ja) 2024-06-07

Similar Documents

Publication Publication Date Title
MX2020010078A (es) Composicion farmaceutica que comprenden timolol.
JP2018531233A5 (es)
MX2020009132A (es) Composiciones farmaceuticas que comprenden nebivolol.
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
WO2018033792A3 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
RU2017129247A (ru) Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
AU2018218696B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
Reibaldi et al. Rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant
MX2022009677A (es) Composiciones para el tratamiento de enfermedades oculares.
MX2020007948A (es) Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
WO2020099925A3 (en) Peptides and pharmaceutical compositions for treating eye diseases
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
EA201891730A1 (ru) Офтальмологическая композиция для применения при лечении офтальмологических расстройств, связанных с изменениями роговично-конъюнктивальной поверхности
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2022000928A (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona.
MX2020011536A (es) Deposito de liquido para liberacion sostenida no invasiva de agentes al ojo.
RU2582284C1 (ru) Офтальмологическая гелеобразная композиция для лечения конъюнктивитов, блефаритов, кератитов с эрозией роговицы, связанных с воспалительными заболеваниями глаза неинфекционной или послеинфекционной этиологии и аллергическими поражениями глазной поверхности
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
AU2020299145A8 (en) Compositions and methods for treating eye diseases
Mehani et al. A comparative study on safety and efficacy of travoprost and brimonidine/timolol fixed combination in patients of primary open-angle glaucoma